Skip to main content

Logout

Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim

Therapeutic Areas
Therapeutic Area

At Boehringer Ingelheim we are driven by the desire to serve mankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our Focus articulates who we are and what we strive for, how we work and what we want to achieve.

Section Overview

Therapeutic Areas

Section Overview

Metabolic

Respiratory

Immunology

Acute Ischemic Stroke
Products
Products

Boehringer Ingelheim is a research-driven group of companies dedicated to the discovery, development, manufacture and marketing of innovative health care products.

See all products

Products

See all products
Resources
Contact us
Double Check Campaign
Logout

Boehringer Ingelheim

Simplicity
Resources

It’s Simple. Not all
DPP4 are the same.

trajenta

Dosing of Trajenta

12/06/2025 | Author: Boehringer Ingelheim

Learn more about Trajenta's Dosing

Document ID: PC-AE-102522 | Expiry Date: 21/04/2029

Resources

Dosing of Trajenta

Safety of Trajenta

Explore Efficacy of Trajenta

Explore Experience of Trajenta

Related Content

Safety of Trajenta

PDF

Safety of Trajenta

PC-AE-102523 (April 2029 )

Download Opens in new tab

Explore Efficacy of Trajenta

PDF

Explore Efficacy of Trajenta

PC-AE-102435 (April 2029 )

Download Opens in new tab

Explore Experience of Trajenta

PDF

Explore Experience of Trajenta

PC-AE-102436 (April 2029 )

Download Opens in new tab

Home
Metabolic
Trajenta
Resources
Dosing of Trajenta

Vault id: PC-AE-102522

Sitemap

Therapeutic Area

Resources
- Videos
- Clinical studies

BI

Site Map
Privacy Policy
Terms & Conditions
Contact

.

© 2010-2023 Boehringer Ingelheim International GmbH. All rights reserved. PC-AE-101941